A carregar...
Publicação
Monitorização Serológica de SARS-CoV-2 Após Vacinação em Profissionais de Saúde
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 3.68 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
A resposta imunitária à vacinação contra a COVID-19 é um dos temas mais em foco
atualmente, levantando legítimas dúvidas no que se refere a pontos essenciais no
combate à pandemia, nomeadamente no que se refere à sua eficácia ou à duração da
proteção conferida pelas diferentes vacinas.
O objectivo principal deste estudo foi avaliar a resposta imunitária humoral à vacinação
nos profissionais de saúde. Secundariamente pretendeu-se comparar os resultados
obtidos com um método comercial (anticorpos IgG anti-S) com três ensaios comerciais
de neutralização, de forma a determinar a correlação entre estes métodos.
O estudo envolveu 188 participantes, os quais receberam vacinas da Pfizer,
Astrazeneca, Moderna ou Johnson. Dentro dos resultados obtidos destacam-se:
- nas amostras colhidas após a 1ª dose da vacina os valores de anticorpos IgG Spike
foram mais elevados nos vacinados com a vacina Pfizer e mais baixos na vacina
Johnson;
- 6 meses após a 2ª dose da vacina, os níveis de anticorpos IgG Spike diminuíram;
- após a 2ª dose da vacina os valores mais elevados de anticorpos encontram-se no
grupo de participantes que receberam as duas doses da vacina da Pfizer;
- todos os participantes, à exceção dos vacinados com a vacina Johnson, possuíram
anticorpos para as 3 variantes do SARS-CoV-2 testadas, o vírus inicial, a variante Delta
(B.1.617.2) e a variante Omicron (B.1.1.529).
The immune response to vaccination against COVID-19 is one of the topics most in focus today, raising legitimate doubts with regard to essential points in the fight against the pandemic, namely with regard to its effectiveness or the duration of protection provided by the different vaccines. The main objective of this study was to evaluate the humoral immune response to vaccination in healthcare professionals. Secondly, it was intended to compare the results obtained with a commercial method (anti-S IgG antibodies) with three commercial neutralization assays to determine the correlation between these methods. The study involved 188 participants, who received vaccines from Pfizer, Astrazeneca, Moderna or Johnson. Among the results obtained, the following stand out: - in the samples collected after the 1st dose of the vaccine, the IgG Spike antibody values were higher in those vaccinated with the Pfizer vaccine and lower in the Johnson vaccine; - 6 months after the 2nd dose of the vaccine, the levels of IgG Spike antibodies decreased; - after the 2nd dose of the vaccine, the highest values of antibodies are found in the group of participants who received the two doses of the Pfizer vaccine; - all participants, with the exception of those vaccinated with the Johnson vaccine, had antibodies to the 3 variants of SARS-CoV-2 tested, the initial virus, the Delta variant (B.1.617.2) and the Omicron variant (B.1.1 .529).
The immune response to vaccination against COVID-19 is one of the topics most in focus today, raising legitimate doubts with regard to essential points in the fight against the pandemic, namely with regard to its effectiveness or the duration of protection provided by the different vaccines. The main objective of this study was to evaluate the humoral immune response to vaccination in healthcare professionals. Secondly, it was intended to compare the results obtained with a commercial method (anti-S IgG antibodies) with three commercial neutralization assays to determine the correlation between these methods. The study involved 188 participants, who received vaccines from Pfizer, Astrazeneca, Moderna or Johnson. Among the results obtained, the following stand out: - in the samples collected after the 1st dose of the vaccine, the IgG Spike antibody values were higher in those vaccinated with the Pfizer vaccine and lower in the Johnson vaccine; - 6 months after the 2nd dose of the vaccine, the levels of IgG Spike antibodies decreased; - after the 2nd dose of the vaccine, the highest values of antibodies are found in the group of participants who received the two doses of the Pfizer vaccine; - all participants, with the exception of those vaccinated with the Johnson vaccine, had antibodies to the 3 variants of SARS-CoV-2 tested, the initial virus, the Delta variant (B.1.617.2) and the Omicron variant (B.1.1 .529).
Descrição
Palavras-chave
COVID-19 SARS-CoV-2 doseamento de anticorpos IgG S IgG N e o ensaio de neutralização